Auro Laboratories Limited has submitted the Outcome of the Board Meeting held on May 30, 2025.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 4.3 pts more than Nifty Microcap 250 and 4.5 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Auro Laboratories' Board met on May 30, 2025 and approved three key items. First, Mr. Kuntal Pancholi was appointed as the new Chief Financial Officer and Key Managerial Personnel, replacing the previous CFO — he brings over 29 years of experience in accounts and finance. Second, M/s. Pokharna and Associates were appointed as Internal Auditors for FY2025-26. Third, the Audited Financial Results for Q4 and full year ended March 31, 2025 were approved, with the statutory auditors issuing an unmodified (clean) opinion. For FY25, total income fell sharply to Rs. 2,005.44 lakhs from Rs. 5,513.91 lakhs in FY24, while profit after tax dropped to Rs. 183.88 lakhs from Rs. 779.21 lakhs, giving an EPS of Rs. 2.95 versus Rs. 12.50 the previous year. Total assets grew to Rs. 9,909.61 lakhs, with capital work-in-progress jumping to Rs. 5,647.52 lakhs and non-current borrowings rising to Rs. 3,308.53 lakhs, indicating significant ongoing capex funded by debt.
Sharp year-on-year decline in revenue and profits is a negative for shareholders, but the heavy capital expenditure (more than doubling CWIP) and higher borrowings suggest the company is investing for future growth. The new CFO appointment and clean audit opinion are routine governance positives, though the dramatic earnings drop will likely weigh on the stock in the near term.